TABLE 3.
Supply of cardiovascular medicines in the participating municipalities over the study period (2017–2018).
| Characteristics of supply | Xiangyang (intervention) | Yichang (control) | ||
|---|---|---|---|---|
| 2017 | 2018 | 2017 | 2018 | |
| Number of INNs | 126 | 92 | 132 | 130 |
| Type of procured products | 229 | 140 | 233 | 236 |
| Generic competitors per product per month (Mean ± SD) | 1.86 (±1.56) | 1.09 (±1.19) | 2.29 (±2.11) | 2.41 (±2.01) |
| Therapeutic competitors per product per month (Mean ± SD) | 6.63 (±5.19) | 3.84 (±3.65) | 7.99 (±5.64) | 8.71 (±6.14) |
| Number (%) of products supplied by: | ||||
| Domestic suppliers outside of top 100 | 141 (61.57) | 78 (55.71) | 139 (59.66) | 128 (54.24) |
| Top 100 domestic suppliers | 13 (5.68) | 18 (12.86) | 8 (3.43) | 26 (11.02) |
| Suppliers with joint venture | 47 (20.52) | 26 (18.57) | 54 (23.18) | 53 (22.46) |
| Foreign-owned suppliers | 28 (12.23) | 18 (12.86) | 32 (13.73) | 29 (12.29) |
| Number (%) of products with: | ||||
| Original brand | 43 (18.78) | 26 (18.57) | 43 (18.45) | 40 (16.95) |
| Generic | 186 (81.22) | 114 (81.43) | 190 (81.55) | 196 (83.05) |
| Number (%) of products administered through: | ||||
| Oral | 141 (61.57) | 89 (63.57) | 151 (64.81) | 162 (68.64) |
| Injectable | 88 (38.43) | 51 (36.43) | 82 (35.19) | 74 (31.36) |
Note: INN - International Nonproprietary Name; SD—standard deviation.